GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics

Issued: London, UK

GSK is committed to tackling antimicrobial resistance (AMR) as part of a sustained, multi-stakeholder response to this global health threat. As one of the few companies actively researching and developing new antibiotics to treat resistant infections, we welcome the UK Government’s long-term commitments to combating AMR. GSK believes that the UK Government commitment to test a new payment model to support antibiotics R&D has the potential to be game-changing and hopes that other countries will follow the UK’s lead. GSK also welcomes the recognition in the UK Government’s long-term plan of the key role that vaccines can play in reducing the need for antibiotics by preventing bacterial, viral and other infections.

Phil Thomson,

President, Global Affairs, GSK        


Back to top